Preclinical investigations have characterized PDZ-RhoGEF, a multidomain signaling effector, as a critical participant in the progression of various cancer types, including glioblastoma and ovarian cancer [31,36]. This evidence concerns the gene ARHGEF11 and glioblastoma.